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ABSTRACT
The human circulation contains cell-free DNA and non-coding microRNA (miRNA). 
Less is known about the presence of messenger RNA (mRNA). This report profiles 
the human circulating mRNA transcriptome in people with liver cirrhosis (LC) and 
hepatocellular carcinoma (HCC) to determine whether mRNA analytes can be used as 
biomarkers of liver disease. Using RNAseq and RT-qPCR, we investigate circulating 
mRNA in plasma from HCC and LC patients and demonstrate detection of transcripts 
representing more than 19,000 different protein coding genes. Remarkably, the 
circulating mRNA expression levels were similar from person to person over the 
21 individuals whose samples were analyzed by RNAseq. Liver derived circulating 
transcripts such as albumin (ALB), apolipoprotein (APO) A1, A2 & H, serpin A1 & E1, 
ferritin light chain (FTL) and fibrinogen like 1 (FGL1) were significantly upregulated 
in HCC patient samples. Higher levels of some of these liver-specific transcripts in 
the plasma of HCC patients were confirmed by RT-qPCR in another cohort of 20 
individuals. Several less abundant circulating transcripts associated with cancer 
were detected in most HCC samples, but not in healthy subjects. Liver specificity 
of circulating transcripts was confirmed by investigating their expression in HCC 
tumor and liver cancer cell lines. Liver specific mRNA sequences in the plasma were 
predominantly present outside circulating extracellular vesicles. 
Conclusions: The circulating “mRNA” transcriptome is remarkably consistent in 
diversity and expression from person to person. Detection of transcripts corresponding 
to disease selective polypeptides suggests the possibility that circulating mRNA can 
work as a biomarker analyte for cancer detection.
INTRODUCTION
We are interested in using mRNA in the blood as 
a source of biomarkers of liver disease. Circulating non-
coding RNA, such as microRNA (miRNA), is routinely 
detected in the blood [1–3]. However, detection and 
understanding of circulating mRNA sequences is in a 
much earlier research phase. Several laboratories have 
demonstrated the existence of circulating mRNA in healthy 
subjects and those with a disease diagnosis [3–13]. For 
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example, circulating hTERT mRNA levels have been 
reported to correlate with a diagnosis of hepatocellular 
carcinoma (HCC) [14, 15] and with tumor progression [12, 
16, 17]. Albumin (ALB) mRNA has also been detected in 
the circulation of advanced stage HCC patients and was 
reported to predict recurrence of HCC after transplantation 
[18, 19]. Additionally, during the preparation of this 
manuscript, circulating mRNA in cardiac disease patients 
was reported [3]. Although there are reports of specific 
mRNAs in select patient populations, a comprehensive 
study or “survey” specifically of circulating mRNA 
transcripts in liver disease patients has not been conducted. 
Circulating mRNA expression profiles, diversity, 
consistency, and heterogeneity across individuals is not 
clear. Also, the extent to which circulating mRNA is derived 
from “non-” blood tissue as opposed to blood or endothelial 
cells that line the blood is not clear. mRNA sequences in the 
blood, originating from non-blood cells, may be rare and/or 
may be representative of pathological events.
In this study, we analyzed total RNA isolated from 
adult human plasma. Briefly, RNAseq was performed on 
total RNA extracted from the plasma of 10 individuals 
with a diagnosis of HCC, 5 individuals with liver cirrhosis 
(LC) and no HCC, and 6 individuals with no evidence of 
liver disease. Seven of the 10 HCC individuals also had 
underlying LC. Protein coding transcripts, or mRNA, were 
readily detected in all plasma samples and liver selective 
mRNA transcripts were particularly prominent in the 
plasma from HCC/LC patients. Some of the circulating 
mRNA transcripts corresponded to genes whose 
expression is known to be altered or mutated in HCC. 
The presence of a selected set of liver specific mRNA 
transcripts in the circulation was confirmed by RT-qPCR 
analysis of another 20 distinct plasma samples.
Although we are ultimately interested in identifying 
circulating mRNA markers of liver disease, this study 
primarily intended to determine if there is a circulating 
mRNA transcriptome, to identify the extent of its 
diversity and consistency from sample to sample, and 
to lay the groundwork for methods that can be used to 
identify transcripts that correlate with a disease diagnosis. 
These parameters of the circulating human liver mRNA 
transcriptome are discussed.
RESULTS
Circulating RNA represents diverse transcripts 
from various tissues
To evaluate the presence and diversity of mRNA 
transcripts in the human circulation, we performed RNAseq 
analysis on “total” cell-free RNA from the plasma of 10 
individuals with HCC and LC, 5 with LC alone, and 6 
“normal” healthy controls (NHC), bringing the total number 
of samples analyzed by RNAseq to 21 (Table 1). The HCC, 
LC, and healthy individuals were similar in age. Although 
both genders and those with HCC and LC with and without 
chronic viral hepatitis were included in all liver disease 
categories, balance was not achieved with this opportunistic 
set. For each sequenced sample, more than 50 million reads 
were generated and transcript abundances are reported as 
transcripts per million (TPM). Our methods were designed 
to reduce ribosomal RNA (rRNA) and mitochondrial RNA 
(mtRNA) (Supporting Information). Results of the circulating 
transcripts were first organized by abundance (sorted by 
highest to lowest TPM in normal plasma) and then highly 
abundant transcripts from the top quadrant/upper quartile 
were investigated for the frequency of each RNA category. 
Among the ~19,000 distinct mRNA transcripts found in 
circulation, 65–75% of the coding transcripts represented 
the top quartile of all circulating RNA isolated using our 
method and this result was consistent across different clinical 
categories (Figure 1A). However, when analysis was based 
upon the entire transcriptome (instead of just the 75–100% 
most abundant transcripts), mRNA represented only 15% of 
the identified circulating RNA (Supplementary Figure 1).
It was of interest to track the original tissue source/s of 
circulating coding transcripts. Therefore, RNAseq data from 
each of the HCC (n = 10), LC (n = 5), and NHC (n = 6) 
plasma samples, as well as HCC (n = 2) and normal liver 
(n = 1) tissues were analyzed using TissueEnrich software 
(see Materials and Methods). The most abundant 1,200 
mRNA transcripts were investigated. As shown in Figure 1B, 
circulating mRNA in NHC subjects, which included samples 
from equal numbers of both genders, contained coding 
transcripts from a variety of organs (liver, bone marrow, 
stomach, esophagus, prostate). The plasma from those with 
HCC and, not surprisingly, normal liver and liver tumor 
tissue was greatly enriched for transcripts identified as liver 
derived. Of note is that plasma from the 5 individuals with 
LC (but no HCC) was reduced in liver derived transcripts. 
This result is curious since plasma from people with HCC 
was not reduced in liver derived transcripts, yet most (7 
of 10) of those with HCC were also diagnosed with LC. 
This finding could be an artefact of the small sample size 
and not be representative of larger populations or perhaps, 
most likely, the presence of HCC influences liver transcript 
levels in the circulation. The apparent reduction in amount 
of female organ transcripts in the HCC samples reflects the 
male gender imbalance in this sample set. Taken together, 
these data show that the liver is a major source of coding 
RNA (mRNA) present in the circulation. The presence of 
liver derived mRNA transcripts in the circulation of HCC 
patients provides strong evidence that non-blood mRNA 
transcripts can be readily detected in circulation.
Expression profiles of circulating mRNA 
transcripts show minimal variability between 
individuals
The consistency in levels (TPM) of any specific 
coding transcript between plasma samples was determined 
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by calculating the fold change of a transcript between the 
HCC and NHC samples and between the LC and NHC 
samples. Figure 2A is a dot plot comparing log10 (fold 
change) between the HCC (n = 10) and NHC (n = 6) patient 
plasma and shows that more than 94% of the identified 
genes’ expression profiles varied less than 4 to 8-fold 
between the cohorts. Figure 2B shows a volcano plot of the 
-log10 (fold change) of the variation between HCC (n = 10) 
and NHC (n = 6) versus the p-value of the same variation, 
and also suggests that the human mRNA transcriptome does 
not vary significantly from person to person (genes centered 
in the plot), at least for the individuals of differing age, 
Table 1: Plasma samples used for RNAseq
n Age Gender
n = M/F
HBV/HCV/NAFL/NASH LC (n) HCC stages (n) HCC Stages (n)
AJCC I, II or 
BCLC A, B
AJCC III or 
BCLC C, D
NHC 6 60.0 3/3 0/0/0 N/A N/A N/A
LC 5 59.6 5/0 3/3/0 5 N/A N/A
HCC 10 62.7 7/3 1/7/2 8 6 4
Early cancer (AJCC I, II; Barcelona A, B); Late (AJCC III; Barcelona C, D). N/A, Not Applicable. Plasma from 21 different 
individuals was used. N = 6, from “normal healthy controls” (NHC), n = 5 from those with a diagnosis of liver cirrhosis (LC) 
and n = 10 from those with a diagnosis of hepatocellular carcinoma (HCC) and LC. For the HCC group: 7 of the 10 were also 
diagnosed with LC, 2 with NAFL; 6 BCLC A, B or AJCC I, II; 2 BCLC C, D or 2 with AJCC III A & B. Ages and gender 
(Male [M], Female [F]), as indicated. Individuals with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) or no 
evidence of viral hepatitis were included, as indicated. Diagnosis of HCC, LC and chronic viral hepatitis as in text.
Figure 1: Profile of RNA present in the circulation. (A) Categories of the most abundant transcripts in the plasma from a cohort 
of HCC, LC, and NHC plasma samples. Pie charts represent the proportion of transcript types expressed in the top 25th percentile (75% 
to 100% most abundant) of HCC (n = 10), LC (n = 5), and NHC (n = 6) plasma samples. Charts were generated by first identifying the 
top 25% abundant transcripts and then counting how often each category appeared. (B) Tissues of origin of mRNA transcripts detected in 
human plasma. Five different sample sets were compared: NHC plasma (n = 6), HCC plasma (n = 10), LC plasma (n = 5), normal liver 
tissue (n = 1), and HCC tumor tissue (n = 2). The top most 1,200 abundant protein coding genes in each sample category were analyzed 
using TissueEnrich software (see Materials and Methods) and compared with tissue specific genes from publicly available RNAseq datasets 
(Human Protein Atlas and GTEx using algorithm [49]). Tissue enrichment is expressed as fold change in each category.
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gender, and clinical condition analyzed here. Remarkably, 
the mRNA expression profile for each gene was generally 
consistent from person to person.
The consistency of expression profiles was also 
reflected in scatter plots with log2 (TPM) values for 
the 1,000 most abundant genes from each member of 
the NHC, HCC, and LC categories plotted against each 
gene’s average log2 (TPM) (data not shown). Consistent 
expression profiles were evident when the average log2 
(TPM) values of each disease category were plotted 
against each other (Figure 2C). Most striking from this 
analysis, which includes all 21 plasma samples, was the 
consistency in transcript expression, for any given gene, 
from sample to sample. It is clear from the scatter plots 
that the closer a value plotted to a diagonal line (slope 
= 1), the closer it was to the average transcript amount, 
which indicated degrees of similarity or departure from 
the norm. It is noted that the highly abundant transcripts 
varied the least from patient to patient, the HCC patients 
had the greatest variability, and the variability was extreme 
for a subset of circulating transcripts.
These data collectively suggest that the circulating 
human transcriptome is relatively consistent from person 
to person, based on samples that range in age, gender, and 
liver disease category. That said, even though more than 
94% of the gene transcripts between HCC vs. NHC and 
LC vs. NHC (data not shown) did not show more than 
8-fold variation, there were some differences in mRNA 
expression patterns between HCC and healthy subject 
samples that offer the possibility of identifying disease 
selective biomarker transcripts.
Liver derived mRNA sequences are among the 
most abundant transcripts in circulation
Although most of the circulating coding transcripts 
did not vary significantly in expression from person 
to person (Figure 2), some features of the expression 
analysis are notable. The detection of mRNA transcripts 
in the plasma that correspond to polypeptides derived from 
or enriched in the liver, such as ALB, APOA1, APOA2, 
APOB, APOH, SAA2, SERPINA1, SEPP1, ORM2, etc. 
(Figure 3A), and from other non-blood cells was striking 
and provides evidence that the circulation contains 
mRNA that originated in the liver and not from artefacts 
of the phlebotomy process. These liver derived transcripts 
were upregulated in the circulation of HCC patients 
as compared to those with LC. Figure 3A represents 
expression patterns (log2 (TPM)) of some abundant (base 
mean TPM between 200 (AGT) and 9133 (ALB)) liver 
derived transcripts reflecting 3 to 7-fold higher levels 
compared to those of LC patients (p < 0.01).
A subset of 50 circulating transcripts was identified 
for their differential expression between HCC and NHC 
groups and between LC and NHC groups. Briefly, 
the expression levels of the 50 transcripts, relative to 
the mean level of expression of each transcript, was 
determined and is illustrated using a heat map (Figure 
3B). Hierarchical clustering of the expression profiles in 
21 plasma samples shows that the HCC samples clustered 
together in the heat map (Figure 3B). HCC samples did 
appear to selectively have a common subset of elevated 
levels of mRNA transcripts. Additionally, some circulating 
transcripts selectively upregulated in HCC samples 
correspond to genes associated with malignancy and, in 
many cases, HCC (e. g., DUSP3 [20, 21], coagulation 
factor VII (F7) [22], FAS [23], ITGA9 [24, 25], NBPF12 
[26], SNX16 [27], SDF2L1 [28–30], STRA13 [31], TRAP1 
[32], SERPINE1 [33]). It is worth mentioning that the 
expression levels of 8 different transcripts corresponding 
to 5.8S rRNA were highly uniform in all samples analyzed 
by RNAseq, underscoring the accuracy and authenticity 
of RNAseq analysis and circulating expression profiles 
(data not shown). Despite using a method that aimed to 
minimize detection of mtRNA and rRNA, we observed 
that mitochondrial and ribosomal transcripts were the most 
highly abundant mRNA derived transcripts with uniform 
expression in the circulation of all individuals and could 
have been contributed by any organ or cells present in the 
blood (Supplementary Figure 2).
Expression of circulating transcripts in HCC 
tumor and HCC cell lines
Figure 1B above demonstrates that a substantial 
proportion of transcripts in the plasma of HCC patients 
are liver derived. Similarly, HCC tumor associated 
transcripts almost exclusively correspond to liver tissue. 
RNAseq data strongly suggest increased levels of a subset 
of liver specific transcripts in the circulation of HCC 
patients. Using the Human Protein Atlas (HPA) tissue gene 
expression dataset, which includes expression levels from 
37 human tissues based on RNAseq, we identified a set of 
transcripts that are very selective for liver tissue, including 
ALB, HP, APOA2, APOH, SERPINA1, ORM1, and HPX. 
The genes’ extreme liver specificity is demonstrated 
in Figure 4A. The levels of these transcripts were then 
experimentally determined in a set of liver cancer cell 
lines and a moderately differentiated human tumor 
tissue (HCC103T) using RT-qPCR and are illustrated in 
Figure 4B. Expression levels were normalized with levels 
of corresponding transcripts in immortalized nonmalignant 
PH5CH liver cells. Our data demonstrate significant 
overexpression (p < 0.01) of these transcripts in tumor 
tissue, as well as cancer cell lines (Figure 4B).
Validation and detection of circulating mRNA by 
RT-qPCR
To validate the presence of specific transcripts 
in patient circulation, we investigated a set of clinical 
samples that were studied earlier by RNAseq. RT-
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qPCR assays were carried out on circulating RNA 
from HCC patients (n = 4) and age and gender matched 
healthy controls (n = 4), and expression profiles of six 
liver derived transcripts were studied (Supplementary 
Figure 3). Data showed consistent expression profiles 
using RNAseq and RT-qPCR. Validation of circulating 
transcripts allowed for testing of specific mRNA 
transcripts in an additional independent set of samples 
from 20 individuals (10 with a diagnosis of HCC and 
10 age and gender matched healthy subjects). In these 
20 samples, the prevalence of 4 circulating liver specific 
transcripts, FTL, APOA2, SERPINA1, and ALB, was 
examined by RT-qPCR using exon specific primers 
(Supplementary Table 1). Figure 5A shows the results as 
average cycle threshold (Ct) values in samples from the 
HCC patients and NHCs. Ct values reflect the number of 
PCR cycles required for the fluorescent signal from the 
amplified product to cross a threshold or background. 
Primers specific for exons generated detectable products 
relatively consistent in amount from patient to patient. 
However, consistent with RNAseq data from the 
previous cohort, the transcripts tested were generally 
significantly upregulated in HCC samples as compared 
to the healthy subjects. Relative expression in HCC 
patients was calculated by normalizing with the Ct values 
of an internal reference control and also those of age and 
gender matched NHCs (Figure 5B). Figure 5B represents 
the same data as relative expression of APOA2, ALB, 
FTL, and SERPINA1 transcripts in each HCC patient 
sample in comparison to the average amount present 
in the NHCs (n = 10). Again, although the number of 
patient and healthy subject samples analyzed are too 
small to draw conclusions, the trends of elevated levels 
of these transcripts in HCC samples relative to healthy 
subjects observed with the sample sets used in RNAseq 
does seem to be sustained. Indeed, some HCC samples 
Figure 2: Human circulating transcriptome is essentially similar from person to person. (A) Transcript abundance (TPM) 
corresponding to each of ~19,000 coding regions in each sample as a function of fold difference from the mean of all samples. Plot of 
log10 (fold change) of the variation between HCC (n = 10) and NHC (n = 6) for each gene. (B) Volcano plot of the -log10 (fold change) of 
the variation between HCC (n = 10) and NHC (n = 6) vs. the p-value of the same variation. Genes toward the center of plot do not show 
significant variation, while those that are spread out show significant differences in terms of TPM. (C) The 1,000 most abundant circulating 
transcripts corresponding to protein coding genes graphed for each sample subset. Comparison of average gene expression (log2 (TPM)) of 
the top 1,000 transcripts between HCC vs. NHC, HCC vs. LC, and LC vs. NHC categories.
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Figure 3: Expression profiles of unique circulating transcripts in liver disease. (A) Expression profiles (log2 (TPM)) of some 
abundant liver derived circulating transcripts with 3 to 7-fold higher expression in HCC samples compared to LC samples (p < 0.01). (B) 
Hierarchical clustering of differentially expressed genes. Differentially expressed transcripts were identified by sorting the normalized 
TPMs around the mean (zero) such that the scaled TPM values for HCC vs. NHC and LC vs. NHC are opposite in signs (negative, low 
expression and positive, high expression) and the difference between group averages was at least (± 1.5). The TPM values were scaled for 
each gene with the formula (x-µ)/σ, where x is variable data point, µ and σ are the average and standard deviation for a gene, respectively, 
with color scheme YlOrRd (yellow, orange, red).
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had 9 to 20-fold elevations in liver specific transcripts 
compared to LC samples.
Liver derived circulating transcripts 
predominantly map to genomic exons and 
represent mature mRNA
If the RNA sequences detected in the circulation 
were derived from mRNA, the transcripts should 
align with genic exons and lack intronic sequences 
as introns are not present in most mature mRNA. We 
analyzed the read piles for 6 liver derived transcripts 
from at least 10 individuals (5 HCC, 5 NHC) and found 
substantial representation of exons in sequencing reads. 
As an example, Figure 6 shows read pile profiles of 
three circulating mRNA transcripts (APOA2, FTL, and 
SERPINA1) in 8 distinct plasma samples. The data 
show that the sequencing reads of circulating transcripts 
predominantly correspond to exonic regions and that 
certain specific regions within exons are detected at a 
higher sequencing depth than other regions within a 
given transcript. To confirm the selective detection 
of exons in liver derived transcripts, nested semi-
quantitative PCR was performed on total, cell-free, 
DNase-treated RNA isolated from patient samples. 
Primers for APOA2 that amplify either intronic or 
exonic sequences (that span the intron) were used. Our 
data show the detection of exon specific products alone 
without any intron specific or intron containing PCR 
products (Figure 7A). Further, detection of APOA2 
and FTL transcripts in patient plasma samples was also 
validated by nested PCR and LICOR 800 probe based 
Southern blotting (Figure 7B, Supplementary Table 1). 
The sensitivity of amplicon product detection increased 
when mRNA was either amplified using nested PCR 
or hybridized to gene specific probes via Southern blot 
Figure 4: Liver specificity of circulating transcripts investigated in Human Protein Atlas (HPA) dataset, HCC tumor, 
and cell lines. (A) Expression profiles of transcripts were evaluated in HPA dataset (version 19.2, Ensemble version 92.38) representing 
expression levels in 37 human tissues based on RNAseq. Y-axis reflects expression in transcripts per million (TPM). (B) Relative expression 
of some liver specific transcripts was investigated in a tumor tissue (HCC103T) and cancer cell lines HepG2 and Huh7. Expression profiles 
were normalized with GAPDH expression and expression in non-malignant PH5CH liver cells. Each RT-qPCR reaction was carried out at 
least in triplicate and data are represented as mean values. Significant upregulation in comparison to control PH5CH cells is reflected by 
asterisk sign (p < 0.01).
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(Figure 7B lower panel). Detection of a set of liver 
derived circulating transcripts in HCC plasma samples 
was also demonstrated using nCounter Elements assay 
(Nanostring technology), which directly measures mRNA 
transcripts without the need for reverse transcription and 
PCR amplification (data not shown).
Liver derived transcripts predominantly 
detected outside extracellular vesicles (EVs) in 
circulation
Extracellular vesicles (EVs) consisting of 
exosomes and microvesicles (MVs) are small membrane-
Figure 5: Validation of liver derived circulating transcripts by RT-qPCR in an independent dataset. (A) Relative 
expression of liver specific circulating transcripts in a cohort of 10 HCC patients compared to 10 age/gender matched normal healthy 
control (NHC) samples was investigated by RT-qPCR. Average Ct values in HCC and NHC samples are plotted. Statistical significance was 
calculated by unpaired Student’s t-test. (B) Relative expression calculated by ∆∆Ct method. ∆Ct values of HCC samples were calculated by 
subtracting spike-in ultramer Ct from Ct of target transcripts. Ct values of 10 NHC samples were averaged and normalized with respective 
ultramer Ct values to get an average NHC ∆Ct. ∆∆Ct of HCC samples was calculated by subtracting average NHC ∆Ct from each HCC 
sample ∆Ct. Relative expression calculated by formula 2-∆∆Ct plotted as bar graphs. Each qPCR reaction was run at least in triplicate and data 
are represented as mean values. Sequence of oligos used can be found in Supplementary Materials and Methods.
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enclosed particles of endosomal and plasma membrane 
origin, respectively, that are released by cells into the 
extracellular environment. These membrane-bound 
vesicles represent an important mode of intercellular 
communication. miRNA and other “cargo” from 
intracellular compartments, expressed in the circulation, 
have been reported to be contained within EVs (reviewed 
in Couto et al. [34]). It has been suggested that circulating 
EVs can be used as noninvasive biomarkers for early 
detection, diagnosis, and treatment of cancer [35]. Our 
analysis on plasma, so far, used methods that did not 
distinguish between mRNA contained within or outside 
of EVs. It was therefore of interest to determine if the 
circulating transcripts are located within EVs or circulate 
as membrane-free molecules (EV-free).
To optimize the purification of EVs in plasma 
samples, we first evaluated EV isolation from liver cancer 
cell lines. Figure 8A shows the enrichment of unique EV 
markers CD9, CD63, CD81, and Alix by immunoblotting. 
EV isolation was then carried out with HCC and LC patient 
plasma samples and further characterization carried out by 
nanoparticle tracking analysis (NTA) and immunoblotting 
(Figure 8B, 8C; Supplementary Figure 4). NTA of these 
samples confirmed particle size ranges between 50 to 150 
μm, which are specifically characteristic of exosomes 
(Figure 8C). RNA was isolated from total plasma and 
two plasma sub-fractions, EV and EV-free, from the same 
patient (HCC101P) and followed by RNAseq analysis. 
The results show that although transcripts such as MT-
CO2, FTL, TMSB4X, HBA1, and other mitochondrial and 
ribosomal transcripts were uniformly present inside and 
outside circulating EVs, liver specific transcripts were 
predominantly abundant in the EV-free fraction. Bar 
graphs (Figure 8D) highlight the differential expression 
(TPM) of circulating transcripts. The results suggest that 
major tissue specific transcripts are predominantly present 
in plasma outside vesicles. Figure 8E shows a snapshot 
of read piles of four circulating transcripts including liver 
specific APOA2 and SERPINA1 in EV/EV-free fractions 
and total unfractionated plasma. Note that FTL and HBA1 
transcripts are represented in both fractions, while APOA2 
and APOE are preferentially detected in EV-free plasma, 
highlighting the differential expression. It is tempting to 
speculate that these transcript fragments might exist as 
protein nucleic acid complexes that ensure protection from 
ubiquitous nucleases in the circulation.
DISCUSSION
Here we show that human plasma, among a diverse 
family of RNA transcripts, contains mRNA corresponding 
to more than 19,000 different coding genes. The differential 
sequencing depths and read pile densities within exons 
suggest that circulating mRNA transcripts likely exist as 
fragments. Investigation into the contents of circulating 
EVs implied that mRNA transcripts are located within and 
Figure 6: Circulating transcripts predominantly map to genomic exons. RNAseq read piles in plasma samples from 4 HCC 
patients and their age and gender matched normal healthy controls (NHC) analyzed in a single flow cell experiment. Alignment to 3 genes 
in 8 samples is shown and suggests that circulating transcript sequences overwhelmingly align to exons and not introns. Histograms show 
relative distribution of detected mRNA reads. Specific regions within exons show higher sequencing depth than others and patterns are 
largely consistent across samples. RefSeq gene model diagrams shown at bottom of read piles.
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outside EVs. Many of these coding transcripts came from 
the liver and other solid organs, and liver derived transcripts 
were predominantly found outside circulating EVs. One 
unique observation is that the level of any circulating 
mRNA transcript was very similar from patient to patient, 
not varying by more than 8-fold for 94% of the different 
gene transcripts, which suggests that the circulating human 
mRNA transcriptome is remarkably consistent.
We demonstrate the upregulation of cancer specific 
transcripts in the circulation of HCC patients compared to 
LC patients. Consistent with our results, a growing body 
of evidence exists supporting the presence of circulating 
mRNA in various cancer patients [11, 12, 36]. Serum 
hTERT mRNA in HCC patients correlated with clinical 
variables such as tumor size, number, and degree of 
differentiation [14]. A multi-centered trial demonstrated 
the sensitivity/specificity of HCC diagnosis by hTERT 
mRNA as 90.2%/85.4% and indicated that it was superior 
to AFP, AFP-L3, and DCP in the diagnosis of HCC [15]. 
Similar performance using serum hTERT mRNA was 
Figure 7: Characterization of circulating transcripts using semi-quantitative nested PCR and Southern blotting. (A) 
APOA2 gene consisting of 4 exons was studied in two clinical samples, HCC11 (cancer patient) and NHC10 (normal healthy control) 
using 100 ng cDNA in each reaction. Two oligo sets were prepared: one set encompassing regions of exon 3 and exon 4 and the other 
set corresponding to the intervening intron (amplifying an 82 bp fragment). A short product of 76 bp was expected to be amplified by the 
former oligo set if no intron was present between the exons in the amplified fragment. Genomic DNA or even unspliced mRNA would yield 
a 470 bp product. Visualized gel demonstrates that the 76 bp APOA2 product corresponding to primers spanning exons 3 and 4 is detected 
and shows higher expression in HCC11 sample compared to NHC10, but intron specific primers do not yield any product. HepG2 cDNA 
was used as a positive control. (B) Two sets of primer pairs, corresponding to PCR1 extended amplicon and nested amplicon were used 
to amplify APOA2 and FTL transcripts in two samples, HCC19 and NHC18. PCR1 was carried out for 30 cycles using extended PCR1 
oligos. PCR1 product was diluted 12.5-fold and subjected to nested PCR using nested oligos. Products were separated by electrophoresis 
on a 2% agarose gel. PCR1 products could not be detected, but the nested APOA2 (47 bp) and FTL (49 bp) products were clearly observed. 
HepG2 cDNA was used as a control. As expected, the inner nested oligo sets yielded smaller products (47 bp for APOA2, 49 bp for FTL), 
while outer PCR1 sets of oligos yielded a larger product (76 bp for APOA2, 113 bp for FTL). Gel resolved PCR1 and nested PCR products 
were transferred to a nylon membrane followed by hybridization with extended PCR1 specific 5′-LICOR 800 tagged oligos. As expected, 
5′-LICOR 800 probes did not detect the nested products. The positive control in lane 1, using PCR1 extended primer set and HepG2 cellular 
cDNA as template, reflects the extended PCR1 products of these transcripts. Lanes 2 and 3 are no template negative controls with either 
extended PCR1 (lane 2) or nested (lane 3) oligos. Lanes 4 and 6 reflect the extended PCR1 products in two patients, while lanes 5 and 
7 represent nested products that are not detected by Southern blot using 5′-LICOR 800 tagged oligos in the same samples. Sequences of 
oligos can be found in Supplementary Materials and Methods.
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demonstrated in breast cancer [17, 37]. Albumin mRNA 
has also been detected in the peripheral blood of advanced 
stage (TNM stages III and IV) HCC patients. While it has 
been reported that liver transplantation in HCC patients 
reduced albumin mRNA below detectable limit, recurrence 
of HCC led to detectable levels of circulating albumin 
mRNA. No circulating albumin mRNA was detected in 
healthy individuals or cirrhotic liver patients [38]. Higher 
levels of plasma albumin mRNA were also detected in LC 
and active hepatitis B patients with a diagnostic sensitivity 
of more than 85% and specificity for detection over 90% 
[39]. Together, these reports clearly highlight the potential 
of circulating RNA in the detection of HCC.
Although the numbers of HCC/LC patients 
represented in our study are too small for conclusive 
statements to be made about the prevalence or correlation 
of specific transcripts with any clinical states, we 
observed striking trends. Plasma samples from HCC 
patients contained elevated amounts of specific mRNAs 
and these samples were “grouped together” by the 
unsupervised analysis of the RNAseq data. Since the 
genes and polypeptides for many of these mRNAs (such 
as ALB, DUSP, FAS, SDF2L1, STRA13, MGAT2) have 
been reported elsewhere in the literature to be associated 
with HCC [15, 20, 29, 40], it is tempting to suggest that 
their presence as mRNA in the circulation is related to the 
Figure 8: Circulating liver derived transcripts predominantly exist outside extracellular vesicles (EVs) in the plasma of 
HCC patients. (A) EVs were isolated from the culture media of HepG2 and Huh7 liver cancer cells and characterized by western blotting. 
Equal amounts of protein samples were loaded and the enrichment of tetraspanin receptors CD9, CD63, CD81, Alix, and TSG101 was 
tested as markers of EVs. (B) EVs from either HCC, LC, or normal healthy control (NHC) plasma samples were extracted using ExoQuick 
kit and further purified using ultracentrifugation. In addition to EV markers Alix, CD63, and CD81, liver specific marker SERPINA1 was 
investigated. FAK was used as a loading control. (C) Characterization of EVs from various plasma samples was done by NTA NanoSight 
NS300 system and NTA software analysis was used to obtain the size distribution and quantitation of particles. (D) Plasma sample from 
an HCC patient (HCC101P) was fractionated into EV fraction and remaining EV-free fraction. RNAseq analysis was carried out on RNA 
from total plasma and its two fractions. Comparative expression profiles (TPM) of circulating transcripts within and outside EVs for more 
than 20 liver derived transcripts are shown. (E) Read piles of some of the liver specific transcripts shown above in 6D for whole patient 
plasma, EVs, and EV-free fraction highlight the differential expression. FTL and HBA1 show almost equivalent levels of transcripts within 
and outside EVs, but APOA2 and APOE preferentially exist outside EVs.
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cancer diagnosis, despite the small numbers of samples 
used in this study.
Our data indicate that liver derived transcripts are 
predominantly present outside EVs. Endothelial cells in 
many blood vessels form an uninterrupted vasculature. 
However, as illustrated in Figure 9A, the discontinuous 
architecture and fusion of the luminal and abluminal 
plasma membrane at fenestrae, also called ‘gaps,’ of 
liver sinusoidal endothelial cells (LSECs) constitute a 
permeable barrier between blood cells on one side and 
hepatocytes and hepatic stellate cells on the other side, 
making them the most permeable endothelial cells of 
the mammalian body [41]. Further, the endothelium 
is thickened in HCC and loses its fenestrations while a 
discontinuous basement membrane is formed, resulting 
in vessels that are structurally and functionally abnormal 
[42]. It could be speculated that due to this known leaky 
vasculature in liver and other endocrine organs, detection 
of tissue specific circulating transcripts is not surprising.
The ability to detect mRNA in the blood could 
offer another non-invasive biomarker analyte and a 
liquid biopsy platform to detect and risk stratify disease, 
providing advantages to current non-invasive methods 
(Figure 9B). Primarily, it might be possible to detect 
mRNAs corresponding to non-secretory polypeptides in 
the blood or gene products that are present in extremely 
low abundance and cannot be detected with antibody 
assays. Also, detection of mutant genes and gene 
products is possible and, unlike mutated DNA that is 
usually single or limited copy number per cell, RNA is 
amplified. We have investigated the circulating human 
mRNA transcriptome and demonstrated dysregulation 
of certain liver and cancer specific mRNA transcripts in 
the circulation of HCC patients. However, more work is 
needed to determine biological significance and establish 




Human plasma samples used in this study were 
from the Corporal Michael J. Crescenz VA Hospital, 
Figure 9: Schematic representation of liver sinusoids and loose architecture of liver endothelium. (A) Liver sinusoids. 
Sinusoids are highly modified leaky fenestrated capillaries with large lumens found in the liver, bone marrow, lymphoid tissue, and in some 
endocrine organs. The discontinuous architecture and fusion of the luminal and abluminal plasma membrane at fenestrae or gaps of liver 
sinusoidal endothelial cells (LSECs) result in leaky endothelium. This leaky vasculature may contribute to the transport of cellular cargo, 
extracellular vesicles (EVs), and large molecules like RNA-protein complexes from liver cells into blood. (B) mRNA signatures as potential 
liver disease biomarkers. The leaky endothelium provides an opportunity for development of a liquid biopsy platform for liver diseases, 
including hepatocellular carcinoma, where patient plasma can be tested for the presence of certain disease specific transcripts as biomarker 
analytes and can be effectively used in patient management.
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Philadelphia, PA (CMCVAMC); the University of Texas, 
Houston, TX; and a commercial supplier, BioChemed 
Services, Inc., Winchester, VA. RNAseq was carried out on 
plasma samples from CMCVAMC and BioChemed. Patient 
characteristics are summarized in Table 1 and explained 
in detail in Supporting Materials and Methods. RT-qPCR 
validation was performed on HBsAg positive HCC 
patients, ages 45–75 years (n = 10), and HBsAg/HCC/LC 
negative age and gender matched individual controls (n = 
10) from University of Texas, Houston. Plasma samples 
and, in some cases, parallel tumor tissues from BioChemed 
were derived from both males and females (aged 57–74), 
with HCC histologically confirmed and staging provided. 
All samples used in our study were collected with informed 
consent in writing under IRB approved protocols.
RNAseq experiment and analysis
Total RNA from 1–2 ml plasma samples (spun 
at 2,000g for 5 minutes) was prepared using the Qiagen 
RNeasy Serum/Plasma Kit (Qiagen, Valencia, CA, USA) 
and quantified on a NanoDrop spectrophotometer. RNAseq 
analysis was carried out at Cancer Genomics Facility at 
Thomas Jefferson University (TJU), Philadelphia, PA, 
USA. RNA purity and integrity was assessed by Agilent 
2100 BioAnalyzer. Libraries were prepared using the 
SMARTer® Stranded Total RNA-Seq Kit v2 (Takara Bio 
USA, Inc., Mountain View, CA, USA). Paired-end sequence 
reads were analyzed according to currently available best 
practices for whole-transcriptome analysis, which include 
alignment onto the current human reference genome 
assembly (GRCh38) using the STAR splice aware aligner. 
Transcript counts and abundances expressed in transcripts 
per million (TPM) were estimated based on GENCODE 
v28 gene annotations using the RSEM algorithm. 
Differential expression between groups was tested with the 
R/Bioconductor DESeq2 package. Tissue specific content 
was generated using the R/Bioconductor TissueEnrich 
package [43] (see Supporting Materials and Methods). 
Read piles of liver specific transcripts were analyzed using 
alignment .bam files corresponding to genome version 
GRCh38. The coverage density plots showed how many 
reads were aligned to a specific location, typically lining 
up with exon boundaries. Detailed information is provided 
in Supporting Materials and Methods. Tissue specificity of 
transcripts was also evaluated using Human Protein Atlas 
(HPA) dataset (version 19.2, Ensemble version 92.38), 
representing expression levels in 37 human tissues from 
122 individuals based on RNAseq [44].
RNA extraction from cell lines, tissues, 
extracellular vesicles (EVs), and EV-free plasma
Total RNA was extracted from HCC cell lines HepG2 
and Huh7 and immortalized normal liver PH5CH cells using 
Qiagen miRNeasy Mini Kit (Qiagen, Valencia, CA, USA). 
Total RNA was also extracted from two Grade-2 HCC tumor 
tissues (HCC103T, HCC105T, BioChemed) and a normal 
liver tissue using mirVana miRNA Isolation Kit (Ambion, 
Austin, TX, USA). All kits were used by following 
manufacturer guidelines. Tumor samples corresponding to 
two plasma samples (HCC103P, HCC105P, BioChemed) 
were investigated by RNAseq and one of them (HCC103T) 
was also studied by RT-qPCR. 100 mg tissue treated with 
RNAlater-ICE solution (Invitrogen, Carlsbad, CA, USA) 
was homogenized in a glass homogenizer, worked-up 
following kit protocol, and RNA eluted in 100 µl RNase-
free water. Plasma (3 ml) from HCC101P (BioChemed) was 
spun at 2,000g for 15 minutes to remove cellular debris and 
supernatant was collected. Total RNA from extracellular 
vesicles (EVs) was extracted using the ExoMir Kit 
(BIOO Scientific Corp., Austin, TX, USA). RNA from the 
remaining EV-free flow-through plasma was extracted using 
the Qiagen RNeasy Serum/Plasma Kit (Qiagen, Valencia, 
CA, USA). RNA from plasma EVs, EV-free plasma, and 
liver tissues was sequenced at TJU as described above.
RT-qPCR
RNA samples from cell lines and tumor tissue (2.5 
µg) were subjected to DNase digestion before reverse 
transcription to cDNA. 50 ng qPCR reactions were 
set in triplicate using LightCycler 480 SYBR Green I 
Master reaction mix and LightCycler 480 System (Roche 
Diagnostics, Indianapolis, IN, USA). ∆Ct values were 
calculated by subtracting Ct values of GAPDH in each 
sample from Ct values of target genes. ∆Ct values of tumor 
and HCC cell lines were normalized with ∆Ct values of liver 
PH5CH cells to yield ∆∆Ct values and relative expression 
was calculated using the formula 2-∆∆Ct. RNA from clinical 
plasma samples (1 to 2 ml) was prepared using the Qiagen 
RNeasy Serum/Plasma Kit (Qiagen, Valencia, CA, USA). 
RNA was subjected to DNase digestion before reverse 
transcription to cDNA. Each cDNA sample was spiked 
with specific copy number of a 102 nt zebrafish-specific 
DNA ultramer (IDT, Coralville, IA) for use as internal 
control. PCR reactions for each sample (n = 20) with 25 
ng cDNA were subjected to qPCR. Primers were designed 
corresponding to high sequencing depth regions identified 
from RNAseq (Supplementary Table 1). Relative expression 
of each transcript was calculated using the ∆∆Ct method by 
normalizing with internal reference DNA ultramer and the 
average ∆Ct value (n = 10) from age and gender matched 
NHC samples. Each PCR reaction was carried out in 
triplicate sets and relative expression determined.
Semi-quantitative nested PCR and Southern blots
Clinical plasma samples from HCC patient HCC11 
and NHC10 were investigated for liver derived APOA2 
mRNA. Two sets of oligos were designed. One oligo set had 
forward/reverse primers specific for APOA2 exon 3/exon 4, 
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respectively, and amplified a short product of 76 bp when no 
intron was present in the transcript. The other set consisted 
of oligos specific for the intervening intron between exons 
3 and 4 and amplified an 82 bp fragment. Semi-quantitative 
PCR reactions were carried out using either exon 3 and 4 
specific oligos or oligos corresponding to the intervening 
intron. PCR was carried out for 30 cycles and products were 
resolved by electrophoresis on a 2% agarose gel. For further 
validation and characterization of circulating transcripts, 
nested PCR in clinical plasma samples was carried out 
(HCC patient HCC19 and NHC18) to study APOA2 and 
FTL transcripts. Two sets of oligos, corresponding to 
PCR1 extended amplicon and nested amplicon, were used 
to amplify APOA2 and FTL cDNA. PCR1 was carried out 
for 30 cycles using extended PCR1 oligos. PCR1 product 
was diluted 12.5-fold and subjected to additional 30 cycle 
nested PCR using nested oligos. Both PCR1 and nested PCR 
products were resolved by electrophoresis on a 2% agarose 
gel. Outer PCR1 oligo sets yield a larger product (76 bp for 
APOA2, 113 bp for FTL), while inner nested oligo sets yield 
smaller products (47 bp for APOA2, 49 bp for FTL). PCR1 
and nested PCR products were transferred to an Amersham 
Hybond-N+ membrane (GE Healthcare Life Sciences, 
Marlborough, MA, USA) followed by hybridization with 
extended PCR1 specific 5′-LICOR 800 tagged oligos (IDT, 
Coralville, IA, USA) for Southern blot based detection of 
PCR amplified transcripts. 5′-LICOR 800 probes incorporate 
in PCR1 products, but not in nested products.
Isolation and characterization of EVs
EVs were purified from HepG2 and Huh7 liver 
cancer cell lines as previously described [45, 46] with some 
modifications. Briefly, the culture supernatant was collected 
after 48 hours of starvation, pre-cleared of any cellular 
debris at 2,000g for 20 minutes at 4°C, and centrifuged 
again at 10,000g for 30 minutes at 4°C. The supernatant 
was ultracentrifuged at 100,000g for 120 minutes at 4°C. 
The EV pellet was washed in phosphate buffered saline 
(PBS) at 100,000g for 120 minutes at 4°C and resuspended 
in PBS. Plasma samples (1 to 1.5 ml) from HCC patients 
and normal healthy controls (CMCVAMC) were spun 
at 2,000g for 30 minutes to remove cellular debris 
before purification of EVs using ExoQuick kit (System 
Biosciences, Palo Alto, CA, USA). EVs were further 
purified by ultracentrifugation using PBS at 100,000g for 
120 minutes at 4°C. EV pellet was resuspended in PBS and 
quantified using NanoSight Tracking analysis (Malvern 
Instruments, Malvern, UK). Remaining EV suspension was 
lysed for further characterization. Additional details are in 
Supporting Materials and Methods.
Immunoblotting (IB)
EV isolation and characterization by IB was carried 
out as reported earlier [47, 48]. Blocked membranes were 
probed with either rabbit monoclonal antibodies (mAbs) 
to TSG101 (ab125011) from Abcam (Cambridge, UK) 
and CD63 (55051) and FAK (13009) from Cell Signaling 
Technologies (Danvers, MA, USA) or mouse mAbs to 
human CD81 (ab23505) from Abcam, Alix (sc53540) and 
human CD9 (sc13118) from Santa Cruz Biotechnology, 
Inc. (Dallas, TX, USA), and human SERPINA1 (NBP2-
52557) from Novus Biologicals (Littleton, CO, USA).
Statistical analysis
The reads for each mRNA obtained from the plasma 
of HCC, LC, and NHC patients were analyzed in separate 
generalized linear models with the assumption of negative 
binomial (NB) distribution using the DESeq2 software 
package. The p-values for each set of tests were adjusted 
for multiple testing using the False Discovery Rate (FDR) 
of 1%. RT-qPCR data are shown as mean values and 
considered statistically significant at p < 0.05. GraphPad 
Prism software (San Diego, CA, USA) was used for 
analysis. Western and Southern blot figures were assembled 
in Adobe Photoshop (Adobe Inc., San Jose, CA, USA).
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